Literature DB >> 11675573

Lipoprotein (a) behaviour in patients with hepatocellular carcinoma.

M Motta1, I Giugno, P Ruello, G Pistone, I Di Fazio, M Malaguarnera.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is a malignancy representing in Europe the 3-5% of all malignant tumors. Metabolic pathway of Lipoprotein(a) [Lp(a)] is influenced by various cytokines delivered during inflammatory and neoplastic diseases. Liver seems to be the main site of Lp(a) synthesis.
METHODS: A group of patients affected by HCC was studied in order to evaluate the changes in serum Lp(a) levels and their significance. PARTICIPANTS: 40 patients (25 males and 15 females) affected by primary HCC and 25 control healthy subjects (12 males and 13 females). In HCC patients we evaluated the following serological parameters: Lp(a), total cholesterol (TC), LDL-Cholesterol (LDL-C), HDL-Cholesterol (HDL-C), triglycerides (TG), albumin, (pseudo)cholinesterase (CHE), aspartate amino-transpeptidase (AST), alanine amino-transpeptidase (ALT), gamma-glutamyl transpeptidase (g-GT), alkaline phosphatase (ALP), ferritin, alpha fetoprotein, partial thromboplastin time (PTT), Quick time, prothrombinic activity (PA) and fibrinogen. Statistical analysis of the data obtained was performed using the variance analysis (ANOVA method) and Student's OtO for non-paired data test. For Lp(a), Wilcoxon's non parametric test was used. The correlations between examined parameters were performed by Pearson's correlation test.
RESULTS: In patients with HCC, mean serum TC, LDL-C TG and Lp(a) levels were significantly lower than in controls. HDL-C did not show a statistically significant difference between the two groups studied. Furthermore, we found a positive correlation between: Lp(a) and CHE, Lp(a) and albumin, CHE and LDL-C; while a negative correlation has been found between: Lp(a) and alpha-fetoprotein, Lp(a) and ferritin, CHE and alpha-fetoprotein.
CONCLUSIONS: On the basis of the relationship with alfa fetoprotein and ferritin serum levels, Lp(a) seems to represent an indirect index of liver damage. Lp(a) is a risk factor for vascular diseases and seems to have an interesting role in the liver functions. We conclude that the evaluation of Lp(a) serum levels may contribute, among other markers, to a more complete evaluation of the liver function in patients with HCC suggesting a predictive role for this lipoprotein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11675573

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  25 in total

Review 1.  Serum markers of hepatocellular carcinoma.

Authors:  Giulia Malaguarnera; Maria Giordano; Isabella Paladina; Massimiliano Berretta; Alessandro Cappellani; Mariano Malaguarnera
Journal:  Dig Dis Sci       Date:  2010-03-26       Impact factor: 3.199

2.  MMP-9 polymorphisms are related to serum lipids levels but not associated with colorectal cancer susceptibility in Chinese population.

Authors:  Zhi-Hui Yang; Shi-Ning Li; Jin-Xing Liu; Qing-Xi Guo; Xing-Wang Sun
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

3.  Association of Antituberculosis Treatment and Lower Risk of Hyperlipidemia in Taiwanese Patients: A Population-Based Case-Control Study.

Authors:  Ying-Ray Lee; N I Tien; Cheng-Li Lin; Hsin-Yi Shen; DA-Tian Bau; Yun-Ping Lim
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

4.  Proteomic analysis for developing new biomarkers of hepatocellular carcinoma.

Authors:  Maria Pleguezuelo; Laura M Lopez-Sanchez; Antonio Rodriguez-Ariza; Jose L Montero; Javier Briceno; Ruben Ciria; Jordi Muntane; Manuel de la Mata
Journal:  World J Hepatol       Date:  2010-03-27

5.  Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma.

Authors:  Jian-Min Wu; Nicholas J Skill; Mary A Maluccio
Journal:  HPB (Oxford)       Date:  2010-11       Impact factor: 3.647

6.  Hypercoagulable states in patients with hepatocellular carcinoma.

Authors:  Demetrios N Samonakis; Ioannis E Koutroubakis; Aekaterini Sfiridaki; Niki Malliaraki; Pavlos Antoniou; John Romanos; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

Review 7.  Lipids changes in liver cancer.

Authors:  Jing-Ting Jiang; Ning Xu; Xiao-Ying Zhang; Chang-Ping Wu
Journal:  J Zhejiang Univ Sci B       Date:  2007-06       Impact factor: 3.066

Review 8.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

9.  Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib.

Authors:  Haruhiko Takeda; Hiroki Nishikawa; Eriko Iguchi; Yoshiaki Ohara; Azusa Sakamoto; Keiichi Hatamaru; Shinichiro Henmi; Sumio Saito; Akihiro Nasu; Hideyuki Komekado; Ryuichi Kita; Toru Kimura; Yukio Osaki
Journal:  Mol Clin Oncol       Date:  2012-12-03

Review 10.  Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy.

Authors:  Anne Langsted; Børge G Nordestgaard
Journal:  Curr Atheroscler Rep       Date:  2021-06-20       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.